GSK’S MANY MOVING PARTS (ADD, 26% UPSIDE)
08/04/20 -"When we last pushed GlaxoSmithKline’s (GSK) (Add, UK) investment story in mid-2017, the newly-appointed CEO, Emma Walmsley (consumer health veteran), chose to step out of her comfort zone and ..."
Pages
66
Language
English
Published on
08/04/20
You may also be interested by these reports :
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...
23/04/24
The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...